On September 12, 2019, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing that it has hosted a meeting with investigators in preparation for the launch of the Company’s Phase II clinical trial in China for AlloJoin®, an “off-the-shelf” allogenic human adipose derived mesenchymal progenitor cell therapy product targeting Knee Osteoarthritis. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

99.1 Press Release, dated September 12, 2019

Cellular Biomedicine Group, Inc. Exhibit
EX-99.1 2 cbmg_ex991.htm PRESS RELEASE Blueprint   Exhibit 99.1   Cellular Biomedicine Group Hosts Meeting with Investigators to Launch Phase II AlloJoin® Knee Osteoarthritis Clinical Trial   – First stem cell drug application accepted in China to conduct Phase II Clinical Trial – Orthopedic Doctors representing six class 3AAA hospitals (most specialized)   NEW YORK,…
To view the full exhibit click here

About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.